Southern Archipelago (A33) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
5 Nov, 2026Executive summary
1H2026 revenue fell 33% YoY to S$1.478m; net loss narrowed to S$462k from S$566k. 2Q2026 returned to a S$63k net profit, versus S$24k profit in 2Q2025.
H1 total comprehensive loss widened to S$1.382m from S$800k, mainly reflecting foreign currency translation losses of S$920k versus S$234k.
Financial highlights
1H revenue was S$1.478m, down from S$2.212m; 2Q revenue was S$835k, down 16% YoY from S$995k.
1H loss before tax was S$318k versus S$254k; income tax expense declined to S$144k from S$312k, contributing to the smaller net loss.
Other gains were S$593k in 1H2026 versus net losses of S$82k in 1H2025; the prior period included an S$828k loss on voluntary liquidation of a dormant subsidiary.
Depreciation rose to S$539k from S$375k, mainly due to sterilisation expansion assets; other expenses declined to S$519k from S$579k.
Outlook and guidance
After 1Q2026 net loss of S$525k, 2Q revenue rose 30% QoQ to S$835k and the period returned to S$63k net profit; management expects positive operating cash flow from sterilisation over the next 12 months.
Sterilisation capacity expansion is complete; customer diversification and sales ramp-up are underway, though ramp-up has been slower than planned.
Funding plans include internal resources, shareholder loans, borrowings and/or capital raising as required; management is exploring fundraising and capital structure options.
Latest events from Southern Archipelago
- Sterilisation recovery continues, but liquidity strains and a covenant breach cloud the outlook.A33
Q3 2026 - Revenue and net profit improved, but liquidity and diversification remain key challenges.A33
H2 2023 - A return to modest profit meets weaker revenue and widening working-capital pressure.A33
H1 2024 - Sterilisation expansion continued as lower revenue, a net loss and tight liquidity shaped FY2024.A33
H2 2024 - Sterilisation growth plans amid a S$566k loss, negative working capital and covenant risk.A33
H1 2025 - Revenue fell 17.8%; upgraded capacity meets a strained balance sheet and recovery test.A33
H2 2025 - Revenue fell 47% amid Indonesian headwinds, with liquidity and covenant risks still acute.A33
Q1 2026